French biotech firm Deinove has appointed a new CEO to replace Emmanuel Petiot who resigned from his position in December last year.
Alexis Rideau joins the company from Lyon-based technology research institute Bioaster, where he served as Strategic Partnership Manager and Strategic Partnership Team Coordinator.
Throughout his six years with the firm Rideau has been involved in the implementation of the company’s technology and economic strategy, as well as the valorisation of its tech platforms in the industrial sectors of microbiota, antimicrobials, vaccines and diagnostics.
He also has a PhD in Molecular and Cellular Biology from the University of Cambridge, UK.
Meanwhile, Deinove’s portfolio spans antibiotics and bio-based active ingredients for cosmetics and nutrition-related products; and most recently released a new anti-ageing ingredient, Phy-N-Resist, based on pure phytoene, a colourless carotenoid with strong healing effects.
“The entire team is very pleased to welcome Alexis Rideau,” said Charles Wolder Deinove’s Chairman and acting CEO.
“His scientific expertise and extensive experience in technology transfer and strategic partnerships are assets that will enable Deinove to promote its scientific capabilities to the company’s current and future partners.
“The entire Board of Directors and I are committed to working alongside Alexis to ensure that he takes up his new position in the best possible way.”
Rideau has also held development and analyst roles at Bionest Partners, GlaizerGroup and Bio-Rad Laboratories.
Commenting on his new role, he said: “I am impressed by the potential of the Deinove teams and platforms, and excited by the multitude of projects within which the company can enroll with high added value.
“I will put my energy, my international experience and my industrial, and academic networks at the service of Deinove’s global ambitions and strive to confirm its scientific and technological leadership.”
